New ultrasound technique could spot brain disorders in babies before symptoms appear
NCT ID NCT06940713
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
The CONEXUS study is testing a new type of brain imaging called functional ultrasound (fUS) in 76 newborns at high risk for neurodevelopmental disorders. The technique uses sound waves to measure blood flow changes in the brain, similar to a regular ultrasound but more advanced. Researchers want to see if this painless, bedside scan can detect early signs of conditions like autism or cerebral palsy, potentially allowing doctors to start treatment sooner.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- functional ultrasound imaging (fUS) device
- What this could lead to
- If successful, this could provide a new, non-invasive way to detect early signs of neurodevelopmental disorders in newborns, enabling earlier treatment.
- What could go wrong
- This is an early feasibility study with only 76 participants, so results may not apply broadly. The technique may not reliably predict disorders, and technical challenges like motion artifacts could limit success.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEONATAL ANOXIC-ISCHEMIC ENCEPHALOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Robert Debré
RECRUITINGParis, 75019, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.